ImmunoGen Reports Recent Progress and Second Quarter 2018 Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Grand Canyon Education places CFO on leave amid stock trade probe
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Funds sell $44bn in semiconductors on AI concerns
Immunogen (IMGN) Misses Q2 EPS by 2c, Miss on Revenues
July 27, 2018 6:37 AM EDTImmunogen (NASDAQ: IMGN) reported Q2 EPS of ($0.31), $0.02 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $9.29 million versus the consensus estimate of $13.92 million.
During the second quarter, we made significant progress with mirvetuximab soravtansine, highlighted by FDA Fast Track designation for the treatment of platinum-resistant ovarian cancer, and completion of enrollment in our... More
